ANGPTL3 Inhibitors Market Poised to Reach $3.48 Billion by 2035 as Pipeline Diversifies Beyond Monoclonal Antibodies
核心洞察
The ANGPTL3 (搜索) inhibitors market was valued at USD 0.21 billion in 2025 and is projected to reach USD 3.48 billion by 2035, at a 32.4% CAGR.
Monoclonal antibodies led the market with 71% share in 2025, driven by Regeneron's EVKEEZA, the sole FDA-approved ANGPTL3 (搜索) inhibitor for homozygous familial hypercholesterolemia (搜索).
Arrowhead's zodasiran is advancing into Phase III development following positive Phase IIb ARCHES-2 results, positioning RNAi therapeutics as the fastest-growing drug class.
The ANGPTL3 (搜索) inhibitors market was valued at USD 0.21 billion in 2025 and is projected to reach USD 3.48 billion by 2035, registering a compound annual growth rate (CAGR) of 32.4% from 2026 to 2035, according to a market report from SNS Insider. The market's rapid development stems from an expanding pipeline that has moved beyond a first-in-class monoclonal antibody from Regeneron into RNA interference (RNAi), antisense, and gene-editing therapies, with clinical effectiveness of ANGPTL3 inhibition confirmed for mixed hyperlipidemia (搜索) and severe hypertriglyceridemia (搜索).
The U.S. ANGPTL3 (搜索) inhibitors market was valued at approximately USD 0.11 billion in 2025 and is projected to reach approximately USD 1.64 billion by 2035, at a CAGR of approximately 31.0%. North America led the global market with a 58.0% share in 2025, with the United States accounting for roughly 92.00% of regional revenue. Asia Pacific is expected to grow at the fastest CAGR of about 38.0% from 2026 to 2035.
Pipeline Diversification Beyond Monoclonal Antibodies
The therapeutic landscape is shifting rapidly as development expands beyond monoclonal antibodies into RNAi, antisense, and gene-editing modalities. Arrowhead Pharmaceuticals, Inc. announced plans to begin a Phase III study of zodasiran in patients with homozygous familial hypercholesterolemia (搜索) (HoFH) throughout 2025, following positive Phase IIb ARCHES-2 results demonstrating robust and durable reductions in triglycerides and non-HDL cholesterol among patients with mixed hyperlipidemia (搜索).
Verve Therapeutics, Inc. continued advancing its VERV-201 (搜索) program, an investigational in vivo base-editing therapy designed to permanently reduce ANGPTL3 (搜索) activity, with key clinical program updates anticipated for patients with refractory hypercholesterolemia and homozygous familial hypercholesterolemia (搜索). Ionis Pharmaceuticals, Inc. continued advancing next-generation ligand-conjugated antisense candidates targeting ANGPTL3 through its LICA platform, building on earlier clinical experience from its discontinued vupanorsen program.
Segment Analysis: Monoclonal Antibodies Lead, RNAi Grows Fastest
By drug class, monoclonal antibodies dominated the ANGPTL3 (搜索) inhibitors market in 2025 with a 71% share, while the RNAi therapeutics segment is the fastest growing. The monoclonal antibody segment's leadership reflects the fact that EVKEEZA (evinacumab-dgnb) was the sole FDA-approved ANGPTL3 inhibitor and had been in commercial sales for years ahead of all competitors in clinical trials. Reimbursement channels, real-world clinical data, and lipidologist experience with monoclonal antibodies kept this therapy as the standard of care for homozygous familial hypercholesterolemia (搜索) patients.
The RNAi segment's rapid growth is driven by Arrowhead Pharmaceuticals' advancement of zodasiran into Phase III development, offering infrequent subcutaneous dosing that could substantially improve convenience over intravenous monoclonal antibody infusion. Growing clinical evidence supporting RNAi-mediated ANGPTL3 (搜索) knockdown across broader hyperlipidemia indications beyond the ultra-rare HoFH population continues expanding this modality's addressable patient base.
By indication, homozygous familial hypercholesterolemia (搜索) dominated the market in 2025 with a 64% share, while mixed hyperlipidemia (搜索) is the fastest-growing segment. The HoFH segment's dominance reflects its status as the only indication with an approved therapy and the primary regulatory pathway every pipeline candidate has pursued first, given the ultra-rare disease's clear unmet medical need. The mixed hyperlipidemia segment is growing fastest as Arrowhead's positive Phase IIb ARCHES-2 results demonstrated that ANGPTL3 (搜索) inhibition could address a substantially larger patient population beyond the ultra-rare HoFH indication.
By route of administration, the intravenous segment dominated in 2025 with a 68% share, while the subcutaneous segment is the fastest growing. EVKEEZA is administered as an intravenous infusion at specialty infusion centers and hospitals, sustaining intravenous delivery as the default route. The subcutaneous segment is expected to witness the fastest growth as RNAi and antisense candidates in development, including zodasiran, are designed for infrequent subcutaneous self-administration or brief clinic visits rather than lengthy infusion appointments.
Market Dynamics and Key Players
The industry is driven by rising diagnosed prevalence of homozygous familial hypercholesterolemia (搜索) and other genetic lipid disorders, growing pipeline diversification beyond monoclonal antibodies, increasing clinical evidence supporting ANGPTL3 (搜索) inhibition across broader hyperlipidemia indications, and expanding genetic testing infrastructure improving patient identification. As physician awareness of ANGPTL3's LDL receptor-independent mechanism continues rising, the need for effective treatment options for patients unresponsive to conventional cholesterol therapy continues driving adoption of ANGPTL3-targeted therapeutics.
Key restraints include the substantial cost of ANGPTL3 (搜索)-targeted therapies, which has kept large-scale treatment access concentrated among a comparatively small number of well-resourced specialty lipid centers, and persistent underdiagnosis of homozygous familial hypercholesterolemia (搜索) due to limited genetic testing infrastructure and cascade screening programs in many healthcare systems.
Significant opportunities lie in indication expansion into mixed hyperlipidemia (搜索) and severe hypertriglyceridemia (搜索), as well as advancing in vivo gene-editing platforms offering one-time, potentially permanent ANGPTL3 (搜索) reduction that could fundamentally differentiate treatment economics compared with chronic, repeated-dosing therapies.
Key players in the ANGPTL3 (搜索) inhibitors market include Regeneron Pharmaceuticals, Inc., Arrowhead Pharmaceuticals, Inc., Verve Therapeutics, Inc., Ionis Pharmaceuticals, Inc., Silence Therapeutics plc, Eli Lilly and Company, Novartis AG, Amgen Inc., Alnylam Pharmaceuticals, Inc., Beam Therapeutics Inc., Intellia Therapeutics, Inc., and others.